Enclomiphene to Improve Testosterone - Quick Reference Sheet
evipedia.ai ← Back

Enclomiphene to Improve Testosterone

Created on 08/08/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Enclomiphene is an oral medication that raises a man's own testosterone by removing estrogen's brake on the brain's hormone signals, so sperm production keeps running instead of shutting down. Day-to-day levels are steadier than with testosterone gels. Whether better numbers make men feel better is unsettled. No approved product exists, so supply quality varies. (Full Review)

Protocol

Standard regimen used by leading practitioners
12.5 mg once daily
Escalated to 25 mg daily if four-week morning testosterone is inadequate
Best time of day
Morning
With or shortly after food; places the testosterone trough in the evening, not the working day
Single versus split dosing
Single daily dose
The only regimen tested in the controlled trials; splitting is not supported
Time to effect
Testosterone
2 weeks
Total testosterone and luteinizing hormone rise; steady state typically above 400 ng/dL by four weeks
Sperm production
3 months
One spermatogenic cycle is roughly 72–90 days
Symptoms
Several weeks later
Symptomatic change, where it occurs, trails the biochemical change

Benefits

Contraindications
  • Exogenous testosterone in any form (injections, gels, pellets, oral undecanoate)
  • Primary testicular failure (baseline luteinizing hormone above 12 IU/L with low testosterone)
  • Personal history of venous thromboembolism (especially within 90 days) or known thrombophilia
  • Active or previously treated prostate cancer or male breast cancer
  • Untreated hyperprolactinaemia or an unevaluated pituitary mass
  • Severe hepatic impairment (Child-Pugh Class C)
  • Baseline haematocrit above 54%
  • Untreated severe obstructive sleep apnoea (apnoea-hypopnoea index of 30 or more)
  • Women and adolescents
    •
Key Interactions
  • CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine, duloxetine)
  • CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit juice) and inducers (rifampicin, carbamazepine)
  • Aromatase inhibitors (anastrozole, letrozole, exemestane)
  • Human chorionic gonadotropin
  • Estrogen-containing or thrombogenic agents, and anticoagulants
  • Cimetidine
  • St. John's wort, quercetin, grapefruit-derived extracts, diindolylmethane, calcium-D-glucarate
  • Supplements with additive effects on the same endpoint (boron, tongkat ali, fadogia, ashwagandha, dehydroepiandrosterone)
    •

Risk & Side Effects

  • High: Headache; muscle cramping and spasms; no approved product and unverified supply quality
    •
  • Medium: Mood changes and reduced libido; hot flushes; dizziness; increased urinary frequency; venous blood clots
    •
  • Low: Visual disturbances; breast tenderness and gynecomastia; nausea and gastrointestinal upset
    •
  • Speculative: Reduced insulin-like growth factor 1 signalling; bone density over years; diminishing response over time
    •

Monitoring

Marker Target Why
Total testosterone 600–900 ng/dL Primary efficacy endpoint
Free testosterone 15–25 ng/dL The biologically active fraction, and the one that tracks symptoms
Sex hormone-binding globulin 20–40 nmol/L Explains a good total with a poor free result
Luteinizing hormone 4–8 IU/L on treatment Confirms the axis is being stimulated rather than suppressed
Follicle-stimulating hormone 4–8 IU/L on treatment The signal that underpins the fertility-preservation rationale
Estradiol (sensitive assay) 20–30 pg/mL Detects over-aromatization and guards against over-suppression
Haematocrit 42–48% Detects blood thickening
Lipid panel LDL cholesterol below 100 mg/dL; triglycerides below 100 mg/dL Baseline cardiovascular safety and drug-class check
Prostate-specific antigen Below 1.0 ng/mL under age 60; velocity below 0.35 ng/mL per year Baseline and trend before raising androgens
Prolactin 3–10 ng/mL Excludes a pituitary cause of the low testosterone before treating
Comprehensive metabolic panel Alanine aminotransferase below 30 U/L; fasting glucose 75–90 mg/dL Hepatic clearance and metabolic drift
Semen analysis (concentration and total motile count) Concentration above 15 million/mL; total motile count above 20 million The only direct test of the fertility claim

Cadence: Baseline with two morning testosterone draws 2–10 days apart; recheck at 4–6 weeks and after any dose change, then 3 months, 6 months, and every 6–12 months; semen analysis at 3–6 months

Qualitative Assessment

  • Morning erections and spontaneous libido
  • Energy through the afternoon rather than peak energy
  • Mood stability and irritability
  • Training recovery and session quality, tracked as load and rating of perceived exertion
  • Sleep quality and continuity
  • Absence of visual symptoms, breast tenderness, cramping, and flushing
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.